Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

01 January 2008

Therapeutic Drug Monitoring of tacrolimus in renal transplant patients

B. Solnica, K. Słowińska-Solnica, E. Ignacak, J. W. Naskalski

Ann Transplant 2008; 13(1): 39-40 :: ID: 880202

Abstract

Background: The aim of this study was the retrospective evaluation of the relationship between the dosage of tacrolimus and its blood concentrations in renal transplant patients and assessment of the relationship between blood drug levels and the pharmacological effect.
Material/Methods: The studied group consisted of 64 patients (42 men and 22 women) on combined immunosuppressive treatment using tacrolimus (T), prednisolone (P), mycophenolate (M), azthioprine (A) and sirolimus (S) in various combinations including tacrolimus. The tacrolimus doses ranged from 0.05 to 0.3 mg/kg/day. During the 32-42 weeks follow-up whole blood tacrolimus levels were measured with microparticle enzyme immunoassay on IMx analyzer.
Results: No significant correlation between tacrolimus doses and its blood concentrations was found. Drug levels were within the subtherapeutic range in 89.1% of patients during the entire follow-up. In remaining patients 75-92.3% of results were also subtherapeutic, less than 25% of results were in the therapeutic range, no toxic levels were obtained. The graft rejection was observed in 10.9% patients, men only, 6 on T-P-M treatment (15.8% of T-P-M group) and one on T-P-A treatment. Acute tubular necrosis was observed in
21.9% of patients, 9 men (8 on T-P-M and 1 on T-P-A treatment) and 5 women (2 on T-P-M, 2 on T-P-A and 1 on T-P treatment). All graft rejections and ATN episodes occurred with sub-therapeutic tacrolimus concentrations. Conclusions: No significant dose-concentrations relationship indicates the need for individualized, empiric dosage and therapeutic monitoring of tacrolimus. In majority of studied patients the combined immunosupressive treatment including tacrolimus in subtherapeutic blood levels was effective. Thus, separate therapeutic ranges should be established for combined treatment and for both sexes. On the other hand subtherapeutic drug levels were found in all patients with graft rejection. However, these rejection episodes can not be explained solely by sub-therapeutic tacrolimus concentrations.

Keywords: Tacrolimus, mycophenolate, Cytocheratin 7

Add Comment 0 Comments

In Press

Original article  

Prediction of Renal Graft Function 1 Year After Adult Deceased-Donor Kidney Transplantation Using Variables...

Ann Transplant In Press; DOI: 10.12659/AOT.944603  

Original article  

Impact of Donor-Recipient Relationship on Long-Term Outcomes in Living-Related Donor Kidney Transplantation

Ann Transplant In Press; DOI: 10.12659/AOT.945065  

Case report  

Successful Interventional Therapy for Portal Vein Stenosis after Ex Vivo Liver Resection and Autotransplant...

Ann Transplant In Press; DOI: 10.12659/AOT.944851  

Original article  

Urinary Chemokines CXCL9 and CXCL10 Are Non-Invasive Biomarkers of Kidney Transplant Rejection

Ann Transplant In Press; DOI: 10.12659/AOT.944762  

Most Viewed Current Articles

05 Apr 2022 : Original article   12,880

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

DOI :10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

22 Nov 2022 : Original article   9,836

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...

DOI :10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

12 Jan 2022 : Original article   9,289

Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...

DOI :10.12659/AOT.934738

Ann Transplant 2022; 27:e934738

15 Mar 2022 : Case report   7,052

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358